Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Denise Wilkes

Interventional Pain Medicine Galveston, TX Medical Doctor

NPI 1902812969 CMS profile 131001

301 University Blvd, Galveston, TX 77555

Open in the dashboard

General payments

$98,184

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,502 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Denise Wilkes of Galveston, TX is reported in the CMS Open Payments database as having received $98,184 across 60 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,502 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $262 5
2024 General $254 12
2023 General $225 3
2022 General $234 12
2021 General $25,338 8
2020 General $25,295 5
2019 General $46,577 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Denise Wilkes
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Denise Wilkes were reported at $262. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Denise Wilkes Interventional Pain Medicine median Middle half National median
2019 $46,577 $684 $216–$2,079 $163
2020 $25,295 $382 $122–$1,109 $114
2021 $25,338 $552 $167–$1,554 $132
2022 $234 $605 $187–$1,924 $149
2023 $225 $671 $195–$1,915 $160
2024 $254 $684 $206–$1,837 $164
2025 $262 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $71,546 14 payments
  2. Medtronic, Inc. $25,281 4 payments
  3. Boston Scientific Corporation $384 7 payments
  4. AbbVie, Inc. $314 15 payments
  5. Nevro Corp. $284 3 payments
  6. Allergan Inc. $125 6 payments
  7. ConvaTec Inc. $63 1 payment
  8. Painteq LLC $40 2 payments
  9. Biodelivery Sciences International, Inc. $29 2 payments
  10. Abbott Laboratories $24 1 payment
  11. Other $93 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $95,000 3 payments
  2. Food and Beverage $1,859 51 payments
  3. Travel and Lodging $1,309 5 payments
  4. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMED $1,505 11 payments
  2. INTELLIS ADAPTIVESTIM $265 2 payments
  3. Senza Spinal Cord Stimulation System $263 2 payments
  4. Superion $219 1 payment
  5. BOTOX Botox Therapeutic $169 7 payments
  6. BOTOX Neuroscience $92 5 payments
  7. BOTOX Facial Aesthetics $86 4 payments
  8. AQUACEL AG+ $63 1 payment
  9. UBRELVY $63 3 payments
  10. Intracept $56 1 payment
  11. Other $481 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,046

Median for Anesthesiology: 322

Drug cost

$38,302

Median for Anesthesiology: $8,738

Branded share of claims

36.6%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 28 $12,058
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 251 $9,501
Gabapentin Generic 207 $2,759
Fentanyl Generic 23 $2,231
Morphine Sulfate Er Morphine Sulfate Brand 77 $2,227
Oxycodone Hcl Generic 29 $1,311
Buprenorphine Generic 12 $1,297
Tramadol Hcl Generic 142 $1,293
Pregabalin Generic 78 $1,239
Tramadol Hcl Er Tramadol Hcl Brand 11 $810

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$21,619

Medicare's payments for the services billed

Medicare patients

89

Average age 73

Services billed

369

55 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 34%
Chronic kidney disease 28%
Depression 24%
Heart failure 21%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $107
$107 — —
QULIPTA
  • AbbVie, Inc. $53
$53 — —
UBRELVY
  • AbbVie, Inc. $31
$31 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record